The COHCCC Director has a wide array of advisory input to assist in planning for the Center's future and evaluating the outcomes of Center programs and policy implementation. The most important of these is the day-to-day decision-making body, the Cancer Center Executive Committee. This group consists of the traditional senior leaders of the Center, the Deputy Directors and Associate Directors, as well as several other key senior members of the Center. All plans either originate in or pass through this group. Our External Advisory Board continues to play a significant role in reviewing our plans and advising on our course of action. Our senior leaders. Program Leaders and Core Directors convene in the Cancer Center Leadership Council. The Core Facilities Oversight Committee reviews all Shared Resources activities and services to assure compliance and efficiency. Our Clinical Trials Minority Recruitment Committee is charged with increasing minority enrollment in clinical trials. Our ongoing full Cancer Center retreats and our individual Program retreats are key for promoting and facilitating key collaborations. Strategic planning is a dynamic process that is informally woven into the structure of each of our senior committees, both internal and external. In addition, COHCCC engages in a formal strategic planning process. Key leadership, including the Cancer Center Director and COH Chief Strategy Officer, meet to outline an appropriate process for the development of the objectives and an approach for the CCC strategy document. The approach includes data collection and analysis, multiple interviews with key CCC stakeholders, and an iterative review and approval process of the final deliverable. By design, the plan outlines specific objectives and goals and drives the future direction of the CCC while supporting its mission, vision and aspirations. Performance and progress of the stated goals within the plan are tracked and catalogued on an ongoing basis. Funding is requested for a small portion of the costs for our annual External Advisory Board meeting. Cancer Center retreat and Program retreats.

Public Health Relevance

Ongoing Planning and Evaluation is essential for charting the course of the Cancer Center. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7
Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776
Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :
Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196
Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978
He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :

Showing the most recent 10 out of 1277 publications